Skip to content
  • Sunday, 26 July 2026
  • 2:49 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal
Pharmaceutical R&D

Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal

Teuku Ryan Mar 25, 2026 0

Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…

Read More
Pharmaceutical R&D

Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases

Teuku Ryan Mar 24, 2026 0

Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…

Read More
Pharmaceutical R&D

Novartis Acquires Promising Breast Cancer Drug SNV4818 from Synnovation Therapeutics for Up to $3 Billion

Teuku Ryan Mar 20, 2026 0

Novartis has announced a significant strategic move to bolster its oncology pipeline with the acquisition of SNV4818, an investigational oral…

Read More

Posts pagination

1 … 7 8
MIT Engineers Develop Dual Mode Propulsion System Integrating Chemical and Electric Thrusters for Small SatellitesBrinsupri Poised to Redefine Bronchiectasis Treatment Standards Following Robust ATS 2026 ShowcaseChinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billionOsaka University Researchers Uncover Essential Protein Interaction Governing Sperm Development and Male Fertility
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ